Market closedNon-fractional
BioXcel Therapeutics/BTAI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About BioXcel Therapeutics
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Ticker
BTAI
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
New Haven, United States
Employees
74
Website
www.bioxceltherapeutics.com
BTAI Metrics
BasicAdvanced
$44M
Market cap
-
P/E ratio
-$5.15
EPS
0.32
Beta
-
Dividend rate
Price and volume
Market cap
$44M
Beta
0.32
Financial strength
Current ratio
2.57
Quick ratio
2.367
Long term debt to equity
-140.933
Total debt to equity
-141.42
Interest coverage (TTM)
-10.37%
Management effectiveness
Return on assets (TTM)
-66.96%
Return on equity (TTM)
1,581.24%
Valuation
Price to revenue (TTM)
19.784
Price to book
-0.54
Price to tangible book (TTM)
-0.54
Price to free cash flow (TTM)
-0.289
Growth
Revenue change (TTM)
202.24%
Earnings per share change (TTM)
-22.37%
3-year earnings per share growth (CAGR)
8.30%
What the Analysts think about BTAI
Analyst Ratings
Majority rating from 7 analysts.
BTAI Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$500K
66.67%
Net income
-$27M
20.27%
Profit margin
-5,340.00%
-27.84%
BTAI Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.83
-$1.72
-$0.76
-$0.87
-
Expected
-$1.75
-$1.30
-$0.91
-$0.70
-$0.71
Surprise
4.52%
31.90%
-16.48%
24.58%
-
BTAI News
AllArticlesVideos
BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI™ (dexmedetomidine) Sublingual Film
GlobeNewsWire·2 weeks ago
BioXcel Therapeutics to Present at Jefferies Global Healthcare Conference
GlobeNewsWire·2 months ago
BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for BioXcel Therapeutics stock?
BioXcel Therapeutics (BTAI) has a market cap of $44M as of July 27, 2024.
What is the P/E ratio for BioXcel Therapeutics stock?
The price to earnings (P/E) ratio for BioXcel Therapeutics (BTAI) stock is 0 as of July 27, 2024.
Does BioXcel Therapeutics stock pay dividends?
No, BioXcel Therapeutics (BTAI) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next BioXcel Therapeutics dividend payment date?
BioXcel Therapeutics (BTAI) stock does not pay dividends to its shareholders.
What is the beta indicator for BioXcel Therapeutics?
BioXcel Therapeutics (BTAI) has a beta rating of 0.32. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell BioXcel Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.